…
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Avecho Biotechnology Ltd is an Australian-listed biotechnology company that holds and develops biomedical intellectual property; public filings are limited and the company’s programs and stage of development are not extensively documented. Its long-term growth may be driven by successful R&D progress, regulatory approvals or out-licensing, and partnerships that could support commercialization, offering potential milestone-driven upside.
Key investment risks include high development and regulatory uncertainty, limited transparent public information and liquidity, the likely need for additional financing, and strong competition in the biotechnology sector.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -6.41M | -3.12M | -4.51M | -2.34M | -3.42M |
| Net income | -4.42M | -3.12M | -3.44M | -2.35M | -4.57M |
| Selling general administrative | - | 1.99M | 2.43M | 2.26M | 2.60M |
| Selling and marketing expenses | - | 0.05M | 0.83M | - | - |
| Gross profit | 0.75M | 0.67M | -0.04M | 0.87M | 0.51M |
| Reconciled depreciation | - | 0.14M | 0.18M | 0.23M | 0.67M |
| Ebit | -6.00M | -3.06M | -3.42M | -2.57M | -3.41M |
| Ebitda | -5.87M | -2.92M | -3.24M | -2.34M | -2.98M |
| Depreciation and amortization | 0.14M | 0.14M | 0.18M | 0.23M | 0.43M |
| Operating income | -6.00M | -4.96M | -4.59M | -2.57M | -3.41M |
| Other operating expenses | 7.24M | 6.09M | 5.06M | 4.19M | 5.34M |
| Interest expense | 0.46M | 0.06M | 0.02M | 0.01M | 0.01M |
| Tax provision | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | - | 0.06M | 0.04M | 0.00M | 0.00M |
| Net interest income | - | 0.00M | 0.02M | -0.00M | -0.01M |
| Income tax expense | -2.00M | -1.64M | -1.08M | 0.01M | 1.15M |
| Total revenue | 1.24M | 1.13M | 0.47M | 1.21M | 0.79M |
| Total operating expenses | 6.76M | 5.63M | 4.55M | 3.93M | 5.06M |
| Cost of revenue | 0.49M | 0.46M | 0.52M | 0.34M | 0.29M |
| Total other income expense net | -0.41M | 1.84M | 0.08M | 0.22M | -0.01M |
| Net income from continuing ops | - | -3.12M | -3.44M | -2.34M | -5.15M |
| Net income applicable to common shares | - | -3.12M | -3.44M | -2.34M | -3.42M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 7.11M | 5.00M | 7.32M | 3.35M | 5.25M |
| Intangible assets | - | - | - | 0.03M | 0.10M |
| Other current assets | 0.18M | 1.73M | 0.30M | 0.24M | 0.22M |
| Total liab | 5.55M | 1.73M | 0.94M | 0.92M | 0.71M |
| Total stockholder equity | 1.56M | 3.27M | 6.38M | 2.42M | 4.54M |
| Other current liab | 0.59M | 0.59M | 0.51M | 0.48M | 0.54M |
| Common stock | 246.90M | 244.61M | 244.61M | 237.53M | 237.60M |
| Capital stock | - | 244.61M | - | 237.53M | 237.60M |
| Retained earnings | -246.00M | -269.39M | -239.63M | -264.10M | -262.07M |
| Other assets | - | - | 0.00M | - | - |
| Cash | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M |
| Cash and equivalents | - | - | - | 1.47M | 3.26M |
| Total current liabilities | 0.71M | 1.71M | 0.84M | 0.75M | 0.70M |
| Current deferred revenue | - | - | 0.16M | - | - |
| Net debt | -4.65M | -1.30M | -5.33M | -1.22M | -3.17M |
| Short term debt | 0.01M | 1.06M | 0.08M | 0.07M | 0.08M |
| Short long term debt | - | 0.98M | - | - | - |
| Short long term debt total | 0.01M | 1.08M | 0.18M | 0.25M | 0.09M |
| Other stockholder equity | - | 0.00M | - | 0.02M | 29.00M |
| Property plant equipment | - | - | - | 0.47M | 0.34M |
| Total current assets | 7.06M | 4.81M | 7.00M | 2.85M | 4.81M |
| Net tangible assets | - | - | - | 2.40M | 4.43M |
| Short term investments | - | - | - | 0.09M | - |
| Net receivables | 2.20M | 0.57M | 1.10M | 0.75M | 1.13M |
| Inventory | 0.01M | 0.14M | 0.10M | 0.40M | 0.20M |
| Accounts payable | 0.10M | 0.06M | 0.09M | 0.19M | 0.08M |
| Accumulated other comprehensive income | 0.65M | 28.06M | 1.40M | 29.00M | 29.00M |
| Non currrent assets other | 0.02M | 0.02M | -0.00M | - | - |
| Non current assets total | 0.05M | 0.19M | 0.32M | 0.49M | 0.44M |
| Capital lease obligations | - | 0.10M | - | 0.25M | 0.09M |
| Long term debt total | - | - | - | 0.18M | 0.01M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | - | -0.02M | - | -0.05M | -0.26M |
| Change to liabilities | - | - | - | 0.03M | 0.03M |
| Total cashflows from investing activities | - | -0.02M | 0.00M | -0.05M | -0.20M |
| Net borrowings | - | 0.93M | - | -0.08M | -0.07M |
| Total cash from financing activities | 1.19M | 0.85M | 7.22M | -0.08M | 4.69M |
| Change to operating activities | - | - | - | 0.04M | 0.04M |
| Net income | -4.42M | -3.12M | -3.44M | -2.35M | -5.15M |
| Change in cash | 2.29M | -3.13M | 4.04M | -1.80M | 1.39M |
| Begin period cash flow | 2.37M | 5.50M | 1.47M | 3.26M | 1.87M |
| End period cash flow | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M |
| Total cash from operating activities | 1.10M | -3.97M | -3.18M | -2.27M | 0.43M |
| Issuance of capital stock | - | - | 8.00M | 0.00M | 5.06M |
| Depreciation | 0.14M | 0.14M | 0.18M | 0.08M | 0.43M |
| Other cashflows from investing activities | - | -0.02M | -0.00M | - | 0.00M |
| Change to inventory | 0.13M | -0.04M | -0.06M | -0.21M | -0.10M |
| Change to account receivables | 0.04M | -1.15M | -0.35M | 0.40M | -0.67M |
| Sale purchase of stock | - | 0.00M | -0.72M | 0.00M | -0.29M |
| Other cashflows from financing activities | -0.08M | -0.08M | -0.07M | -0.08M | -0.07M |
| Change to netincome | - | - | - | 0.18M | 0.58M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.05M | 0.20M |
| Change in working capital | 4.92M | -0.93M | -0.39M | 1.04M | 0.52M |
| Stock based compensation | - | 0.01M | 0.10M | - | - |
| Other non cash items | 0.46M | -0.07M | 0.37M | 2.27M | 4.73M |
| Free cash flow | 1.10M | -3.97M | -3.18M | -2.33M | -0.20M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AVE Avecho Biotechnology Ltd |
0.00 20.00% |
0.01 | - | 4.78 | 52.40 | 20.26 | 43.26 | -6.56 |
| CSL CSL Ltd |
-0.40 0.20% |
202.52 | - | 22.73 | 6.16 | 4.50 | 4.84 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.19 1.40% |
13.39 | 90.53 | 172.41 | 5.18 | 6.47 | 3.91 | 48.02 |
| NEU Neuren Pharmaceuticals Ltd |
-0.02 0.09% |
22.98 | 153.33 | 40.32 | 41.94 | 8.75 | 37.82 | 189.88 |
| MSB Mesoblast Ltd |
-0.04 2.33% |
1.89 | - | 454.55 | 20.84 | 3.02 | 16.59 | -9.86 |
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic formulations. Its human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. In addition, the company develops pharmaceutical products; oral, topical, and edible pharmaceutical cannabinoid products, including a cannabidiol TPM soft-gel capsule in Phase III clinical trial for the treatment of insomnia; and non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Paul Gavin BSc (Hons), Ph.D. | Chief Exec. Officer | NA |
| Dr. Roksan Libinaki Ph.D. | Chief Operating Officer | NA |
| Ms. Melanie Jaye Leydin B.Bus, C.A., CA | Company Sec. & CFO | 1973 |
| Dr. Paul Gavin BSc (Hons), Ph.D. | Chief Executive Officer | NA |
| Ms. Melanie Jaye Leydin B.Bus, C.A. | Company Secretary & CFO | 1973 |
| Dr. Paul Gavin BSc (Hons), Ph.D. | Chief Executive Officer | NA |
| Ms. Melanie Jaye Leydin B.Bus, C.A. | Company Secretary & CFO | 1973 |
| Dr. Paul Gavin BSc (Hons), Ph.D. | Chief Executive Officer | NA |
| Ms. Melanie Jaye Leydin B.Bus, C.A. | Company Secretary & CFO | 1973 |
| Dr. Paul Gavin BSc (Hons), Ph.D. | Chief Executive Officer | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.